These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Neuroleptic parkinsonism and tardive dyskinesia and methods of pharmacologically correcting these pathologic conditions (review)]. Arushanian EB Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(2):269-77. PubMed ID: 2858951 [No Abstract] [Full Text] [Related]
7. Tardive dyskinesia: a role for the endogenous opioid system. Sandyk R Med Hypotheses; 1986 Jan; 19(1):71-4. PubMed ID: 2871480 [TBL] [Abstract][Full Text] [Related]
9. Biochemical methods for predicting the occurrence of tardive dyskinesia. Bürki HR Commun Psychopharmacol; 1979; 3(1):7-15. PubMed ID: 38033 [No Abstract] [Full Text] [Related]
10. Adaptive changes in brain dopamine function as a result of neuroleptic treatment. Jenner P; Marsden CD Adv Neurol; 1988; 49():417-31. PubMed ID: 2894127 [No Abstract] [Full Text] [Related]
15. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid. Bishnoi M; Chopra K; Kulkarni SK Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775 [TBL] [Abstract][Full Text] [Related]
16. Dopamine-sensitive adenylate cyclase and receptor binding activities after acute and chronic neuroleptic drug treatment. Clement-Cormier Y Adv Biochem Psychopharmacol; 1980; 24():103-11. PubMed ID: 6105768 [No Abstract] [Full Text] [Related]
17. Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs. Baldessarini RJ; Tarsy D Annu Rev Neurosci; 1980; 3():23-41. PubMed ID: 6106450 [No Abstract] [Full Text] [Related]
18. Use of dopamine receptor agonists to reduce dopamine receptor number as treatment for tardive dyskinesia. Alpert M; Friedhoff AJ; Diamond F Adv Neurol; 1983; 37():253-8. PubMed ID: 6134444 [No Abstract] [Full Text] [Related]